vimarsana.com

Page 36 - ஒன்றுபட்டது மாநிலங்களில் கம்பி குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MicroVision Announces Second Quarter 2021 Results

MicroVision Announces Second Quarter 2021 Results ACCESSWIRE 05 Aug 2021, 06:19 GMT+10 REDMOND, WA / ACCESSWIRE / August 4, 2021 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS based solid state automotive lidar and micro-display technology for augmented reality, today announced its second quarter 2021 results. Revenue for the second quarter of 2021 was $0.7 million, compared to $0.6 million for the second quarter of 2020. MicroVision s net loss for the second quarter of 2021 was $15.0 million, or $0.09 per share, which includes $7.9 million of non-cash compensation expense, compared to a net loss of $2.3 million, or $0.02 per share, which includes $0.2 million of non-cash compensation expense, for the second quarter of 2020. Cash used in operations in the second quarter of 2021 was $6.7 million, compared to cash used in operations in the second quarter of 2020 of $2.9 million. The Company ended the second quarter of 2021 with $135.3 million in cash and cash equivalents, comp

Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation

Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation ACCESSWIRE 05 Aug 2021, 06:05 GMT+10 NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the National Comprehensive Cancer Network ® (NCCN) added REZUROCK TM (belumosudil) tablets to its NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for Hematopoietic Cell Transplantation (HCT) in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease (GVHD). The NCCN Guidelines in the United States now include REZUROCK with a Category 2A designation as a suggested systemic agent for steroid-refractory chronic GVHD. The rapid inclusion of REZUROCK into the NCCN guidelines shortly after full FDA approval validates the potential clinical impact of REZUROCK in this difficult-to-treat therapeutic landscape, said Harlan W. Waks

Treasure & Shipwreck Recovery Announces Treasure Coin Finds and Major Ship Objects

Treasure & Shipwreck Recovery Announces Treasure Coin Finds and Major Ship Objects ACCESSWIRE 05 Aug 2021, 06:19 GMT+10 ST. PETERSBURG, FL / ACCESSWIRE / August 4, 2021 / Treasure & Shipwreck Recovery, Inc. ( TSR or the Company ), (OTC PINK:BLIS) announces the Company, with its partner Gold Hound LLC, has found significant amount of historic coins from a suspected 1715 Fleet Spanish Shipwreck off the operating area off the East Coast of Florida. The coins range from 2, 4 to 8 Silver Reales (2 being smaller and 8 largest) and have been found with significant other shipwreck material in a short time. The finds were made in what has been determined to be a trail of material from offshore leading to large number of targets. Most significantly, only a few dozen target areas out of hundreds surveyed have already yielded these significant finds. The location is associated with a number of 1715 Spanish wrecks found over the years in the area, with large amounts of treasure and historic

Asia Green Biotechnology Corp Secures Financing to Proceed with Research Activities; Enters Investor Relations Agreement

Asia Green Biotechnology Corp Secures Financing to Proceed with Research Activities; Enters Investor Relations Agreement
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.